“Companion Diagnostics”: Has Their Time Come and Gone?

Nir Peled, Gary Palmer, Fred R. Hirsch, Murry W. Wynes, Maya Ilouze, Marileila Varella-Garcia, Lior Soussan-Gutman, Geoff A. Otto, Philip J. Stephens, Jeffrey S. Ross, Maureen T. Cronin, Doron Lipson, Vincent A. Miller, Next-Generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib-Sensitive ALK Rearrangement in a Patient with Metastatic Non–Small-Cell Lung Cancer Journal of Thoracic Oncology. ,vol. 7, pp. e14- e16 ,(2012) , 10.1097/JTO.0B013E3182614AB5

Shengxiang Ren, Fred R. Hirsch, Marileila Varella-Garcia, Dara L. Aisner, Theresa Boyle, Caicun Zhou, D. Ross Camidge, Atypical Negative ALK Break-Apart FISH Harboring a Crizotinib-Responsive ALK Rearrangement in Non–Small-Cell Lung Cancer Journal of Thoracic Oncology. ,vol. 9, ,(2014) , 10.1097/JTO.0000000000000013

Shakun M. Malik, Richard Pazdur, Jeffrey S. Abrams, Mark A. Socinski, William T. Sause, David H. Harpole, John J. Welch, Edward L. Korn, Claudio Dansky Ullmann, Fred R. Hirsch, Consensus report of a joint NCI thoracic malignancies steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of "master protocols" in lung cancer. Journal of Thoracic Oncology. ,vol. 9, pp. 1443- 1448 ,(2014) , 10.1097/JTO.0000000000000314

David R. Spigel, Thomas J. Ervin, Rodryg A. Ramlau, Davey B. Daniel, Jerome H. Goldschmidt, George R. Blumenschein, Maciej J. Krzakowski, Gilles Robinet, Benoit Godbert, Fabrice Barlesi, Ramaswamy Govindan, Taral Patel, Sergey V. Orlov, Michael S. Wertheim, Wei Yu, Jiping Zha, Robert L. Yauch, Premal H. Patel, See-Chun Phan, Amy C. Peterson, Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 31, pp. 4105- 4114 ,(2013) , 10.1200/JCO.2012.47.4189

Oriana Yu, Maria Eberg, Serge Benayoun, Armen Aprikian, Gerald Batist, Samy Suissa, Laurent Azoulay, Use of Statins and the Risk of Death in Patients With Prostate Cancer Journal of Clinical Oncology. ,vol. 32, pp. 5- 11 ,(2014) , 10.1200/JCO.2013.49.4757

Frances A. Shepherd, José Rodrigues Pereira, Tudor Ciuleanu, Eng Huat Tan, Vera Hirsh, Sumitra Thongprasert, Daniel Campos, Savitree Maoleekoonpiroj, Michael Smylie, Renato Martins, Maximiliano van Kooten, Mircea Dediu, Brian Findlay, Dongsheng Tu, Dianne Johnston, Andrea Bezjak, Gary Clark, Pedro Santabárbara, Lesley Seymour, Erlotinib in previously treated non-small-cell lung cancer. The New England Journal of Medicine. ,vol. 353, pp. 123- 132 ,(2005) , 10.1056/NEJMOA050753

Jeffrey A. Engelman, Pasi A. Jänne, Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer Clinical Cancer Research. ,vol. 14, pp. 2895- 2899 ,(2008) , 10.1158/1078-0432.CCR-07-2248

David S. Shames, Ignacio Wistuba, Marina Lipkind, Jenny Huang, Mirella Lazarov, Vanitha Ramakrishnan, Lukas Amler, See-Chun Phan, Premal Patel, Amy Peterson, Robert L. Yauch, Hartmut Koeppen, Wei Yu, Jiping Zha, Ajay Pandita, Elicia Penuel, Linda Rangell, Rajiv Raja, Sankar Mohan, Rajesh Patel, Rupal Desai, Ling Fu, An Do, Vaishali Parab, Xiaoling Xia, Tom Januario, Sharianne G. Louie, Ellen Filvaroff, Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit Clinical Cancer Research. ,vol. 20, pp. 4488- 4498 ,(2014) , 10.1158/1078-0432.CCR-13-1836

D. Ross Camidge, Sai-Hong Ignatius Ou, Geoffrey Shapiro, Gregory Alan Otterson, Liza Cosca Villaruz, Miguel Angel Villalona-Calero, A. John Iafrate, Marileila Varella-Garcia, Sanja Dacic, Stephanie Cardarella, Weiqiang Zhao, Lesley Tye, Patricia Stephenson, Keith D. Wilner, Leonard Philip James, Mark A. Socinski, Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. ,vol. 32, pp. 8001- 8001 ,(2014) , 10.1200/JCO.2014.32.15_SUPPL.8001

David R Spigel, Martin J Edelman, Kenneth O'Byrne, Luis Paz-Ares, David S Shames, Wei Yu, Virginia E Paton, Tony Mok, None, Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial. Journal of Clinical Oncology. ,vol. 32, pp. 8000- 8000 ,(2014) , 10.1200/JCO.2014.32.15_SUPPL.8000